Improving Dolutegravir Delivery For Pediatric HIV Patients - AZoNano

New research presents the fabrication of Dolutegravir-loaded chitosan nanoparticles with improved solubility and bioavailability for the treatment of pediatric HIV patients

Dolutegravir (DTG) is an antiretroviral drug used to treat human immunodeficiency virus (HIV) in adults and children (4 weeks of age and above). However, this drug possesses solubility issues. An art… [+6983 chars]

full article...